Today you can read summaries of the going's on at ASCO as reported in Pharmalot, Fierce Biotech and Xconomy. Clearly the cancer treatment world is heating up and there were a number of exciting clinical trials reported on at this year's meetings. The concensus seems to be the companies following made the biggest splashes (with patients, analysts and investors) with their clinical results.
Who Got The Most Buzz At The Noisy ASCO Fair? // Pharmalot.
In the order mentioned in the Pharmalot post:
- J&J reported on Zytiga for treatment of prostate cancer for patients who have not received chemo
- Roche reported results on its latest stage antibody-drug conjugate, T-DM1, for the treatment of breast cancer. Roche says it has 8 ADCs in the clinic and 25 in its pipeline targeted at cancers
- BMS reported on its drug, BMS-936558, which targets PD-1 in a variety of cancer cells. BMS hopes to establish this as a blockbuster for a number of cancers. PD-1 encourages the patient's immune system to fight the cancer
- Bayer reported on regorafenib for the treatment of stomach cancer. It is also being directed toward colorectal cancers and gastrointestinal stromal tumors
Other notable results were reported by Dendreon (prostate), Ariad Pharmaceuticals (CML), Onyx Pharmaceuticals (colorectal cancer), Aveo (kidney cancer), and GSK (melanoma).
These drugs have the potential to change the standard of care and the "empowered antibodies" being pushed by Roche utilizing technologies from Seattle Genetics or Immunogen look to usher in the world of ADCs with so-called "smart bombs". All and all an exciting conference with exciting results.
Posted by Bruce Lehr June 6th 2012.
In addition to its ADC, T-DM1, Genentech is also awaiting an FDA green light on its new HER2 drug pertuzumab (Perjeta).
http://www.xconomy.com/san-francisco/2012/06/07/genentech-eagerly-awaits-fda-word-on-2nd-breast-cancer-drug/
Posted by: bigredbruce | 06/07/2012 at 10:44 AM